Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Inclusion Criteria: * Men or women 18-65 years of age at time of consent * Chronic plaque-type psoriasis diagnosed for at least 6 months at time of randomization * At randomization, moderate to severe psoriasis as defined by: * PASI score of 12 or greater and, * IGA score of 3 or greater and, * Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater. * Female patients may be included according to the following: Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, using highly effective methods of contraception during dosing and for 5 times the terminal half-life of study treatment. • Male subjects must agree to comply with two highly effective contraceptive methods Exclusion Criteria: * Forms of psoriasis other than chronic plaque-type (incl. drug induced psoriasis) * Ongoing use of prohibited psoriasis treatments and other prohibited medication at randomization. Washout periods detailed in the protocol have to be adhered to * Previous treatment with IL-17 or IL17R blocking agents, including secukinumab * Any live vaccines (including nasal-spray flu vaccine) starting from 6 weeks before screening, during the study, and up to 24 weeks after the last dose of CJM112 or secukinumab * Evidence of active tuberculosis at screening * Active systemic infections (other than common cold) * Pregnant or nursing (lactating) women